ABSTRACT
Four novel Co(II) coordination compounds 1-4 of the general formula [Co(Ln)2][Co(NCY)4]·mCH3CN (where Ln are tridentate ligands L1 = 2,6-bis(1-hexyl-1H-benzimidazol-2-yl)pyridine for 1 and 2; L2 = 2,6-bis(1-octyl-1H-benzimidazol-2-yl)pyridine for 3; L3 = 2,6-bis(1-dodecyl-1H-benzimidazol-2-yl)pyridine for 4, Y = O for 1, 3, and 4 and Y = S for 2; m = 0 for 1 and 3, m = 0.5 for 2 and m = 2 for 4) were prepared and characterised. The molecular structures of all four compounds consist of the hexacoordinate complex cation [Co(Ln)2]2+ and tetracoordinate complex anion [Co(NCY)4]2-, with distorted octahedral and tetrahedral symmetry of coordination polyhedra, respectively. The electronic structures of all compounds feature an orbitally non-degenerate ground state well-separated from the lowest excited state, which allows the analysis of the magnetic anisotropy by the spin Hamiltonian model. ZFS parameters, derived from both CASSCF-NEVPT2 calculations and magnetic data analysis, indicate that tetrahedral anions [Co(NCY)4]2- exhibit small axial parameters |D| spanning the range of 2.2 to 7.7 cm-1, while octahedral cations [Co(Ln)2]2+ display significantly larger |D| parameters in the range of 37 to 95 cm-1. For 1-3, the Fourier-transform infrared magnetic spectroscopy (FIRMS) revealed a reasonable transmission with a magnetic absorption around the expected value for the ZFS accompanied by features allowing to identify phonon frequencies and simulate spin-phonon couplings. Dynamic magnetic investigations unveiled the field-induced slow relaxation of magnetisation, with maximal relaxation times (τ) of 92(2) µs for 2 at 2 K and BDC = 0.3 T. The temperature evolution of τ was analysed using a combination of Orbach, direct and Raman relaxations (Ueff = 8(1) K (5.6 cm-1)) or Orbach, direct and spin-phonon induced relaxations (Ueff = 10.3(9) K (7.2 cm-1)). The rest of the complexes, namely 1, 3, and 4 show field-induced slow relaxation of magnetisation with τ smaller than 16 µs.
ABSTRACT
Antibiotic resistance in staphylococcal strains and its impact on public health and agriculture are global problems. The development of new anti-staphylococcal agents is an effective strategy for addressing the increasing incidence of bacterial resistance. In this study, ethanolic extracts of Cannabis sativa L. made from plant parts harvested during the whole vegetation cycle under various nutritional treatments were assessed for in vitro anti-staphylococcal effects. The results showed that all the cannabis extracts tested exhibited a certain degree of growth inhibition against bacterial strains of Staphylococcus aureus, including antibiotic-resistant and antibiotic-sensitive forms. The highest antibacterial activity of the extracts was observed from the 5th to the 13th week of plant growth across all the nutritional treatments tested, with minimum inhibitory concentrations ranging from 32 to 64 µg/mL. Using HPLC, Δ9-tetrahydrocannabinolic acid (THCA) was identified as the most abundant cannabinoid in the ethanolic extracts. A homolog of THCA, tetrahydrocannabivarinic acid (THCVA), reduced bacterial growth by 74%. These findings suggest that the cannabis extracts tested in this study can be used for the development of new anti-staphylococcal compounds with improved efficacy.
Subject(s)
Cannabinoids , Cannabis , Hallucinogens , Cannabinoids/pharmacology , Plant Extracts/pharmacology , Staphylococcus , Dronabinol/pharmacology , Anti-Bacterial Agents/pharmacology , Hallucinogens/pharmacology , Cannabinoid Receptor Agonists/pharmacology , Ethanol/pharmacologyABSTRACT
Introduction: The use of Cannabis sativa L. in health care requires stringent care for the optimal production of the bioactive compounds. However, plant phenotypes and the content of secondary metabolites, such as phytocannabinoids, are strongly influenced by external factors, such as nutrient availability. It has been shown that phytocannabinoids can exhibit selective cytotoxicity against various cancer cell lines while protecting healthy tissue from apoptosis. Research Aim: This study aimed to clarify the cytotoxic effect of cannabis extracts on colorectal cell lines by identifying the main active compounds and determining their abundance and activity across all developmental stages of medical cannabis plants cultivated under hydroponic conditions. Materials and Methods: Dimethyl sulfoxide extracts of medical cannabis plants bearing the genotype classified as chemotype I were analyzed by high-performance liquid chromatography, and their cytotoxic activity was determined by measuring cell viability by methylthiazolyldiphenyl-tetrazolium bromide assay on the human colon cancer cell lines, Caco-2 and HT-29, and the normal human epithelial cell line, CCD 841 CoN. Results: The most abundant phytocannabinoid in cannabis extracts was tetrahydrocannabinolic acid (THCA). Its maximum concentrations were reached from the 7th to the 13th plant vegetation week, depending on the nutritional cycle and treatment. Almost all extracts were cytotoxic to the human colorectal cancer (CRC) cell line HT-29 at lower concentrations than the other cell lines. The phytocannabinoids that most affected the cytotoxicity of individual extracts on HT-29 were cannabigerol, Δ9-tetrahydrocannabinol, cannabidiol, cannabigerolic acid, and THCA. The tested model showed almost 70% influence of these cannabinoids. However, THCA alone influenced the cytotoxicity of individual extracts by nearly 65%. Conclusions: Phytocannabinoid extracts from plants of the THCA-dominant chemotype interacted synergistically and showed selective cytotoxicity against the CRC cell line, HT-29. This positive extract response indicates possible therapeutic value.
ABSTRACT
At present, Alzheimer's disease (AD) and related dementias cannot be cured. Therefore, scientists all over the world are trying to find a new approach to prolong an active life of patients with initial dementia. Both pharmacological and non-pharmacological pathways are investigated to improve the key symptom of the disease, memory loss. In this respect, influencing the neuromodulator acetylcholine via muscarinic receptors, such as cevimeline, might be one of the therapeutic alternatives. The purpose of this study is to explore the potential of cevimeline on the cognitive functions of AD patients. The methodology is based on a systematic literature review of available studies found in Web of Science, PubMed, Springer, and Scopus on the research topic. The findings indicate that cevimeline has shown an improvement in experimentally induced cognitive deficits in animal models. Furthermore, it has demonstrated to positively influence tau pathology and reduce the levels of amyloid-ß (Aß) peptide in the cerebral spinal fluid of Alzheimer's patients. Although this drug has not been approved by the FDA for its use among AD patients and there is a lack of clinical studies confirming and extending this finding, cevimeline might represent a breakthrough in the treatment of AD.
Subject(s)
Cognition Disorders/drug therapy , Muscarinic Agonists/pharmacology , Neurodegenerative Diseases/drug therapy , Neuropharmacology , Pharmaceutical Preparations/administration & dosage , Quinuclidines/pharmacology , Thiophenes/pharmacology , Animals , HumansABSTRACT
Three Hofmann-like metal-organic frameworks {Fe(bpac)[Pt(CN)4]}·G (bpac = 1,2-bis(4-pyridyl)acetylene) were synthesized with photoisomerizable guest molecules (G = trans-azobenzene, trans-stilbene or cis-stilbene) and were characterized by elemental analysis, thermogravimetry and powder X-ray diffraction. The insertion of guest molecules and their conformation were inferred from Raman and FTIR spectra and from single-crystal X-ray diffraction and confronted with computational simulation. The magnetic and photomagnetic behaviors of the framework are significantly altered by the different guest molecules and different conformations. On the other hand, photoisomerization of the guest molecules becomes strongly hindered by the framework.
ABSTRACT
A series of di-/trinitroxide esters and amides featuring PROXYL and/or TEMPO radicals connected with alicyclic bridges were prepared in 61-92 % yields and their properties were analysed by using multiple experimental techniques. The examination of EPR spectra of radicals in organic solvents augmented with DFT calculations brought valuable information on the conformational dynamics and spin exchange mechanisms. Cyclic voltammetry investigations revealed (quasi)reversible electrochemical behaviour of studied nitroxides with their half-wave potentials ranging from -51 to -17â mV. SQUID measurements of selected radicals revealed that the magnetism of di- and trinitroxides is significantly different, since antiferromagnetic coupling in biradicals is notably larger than in triradicals. The single-crystal X-ray analysis of selected biradicals revealed the existence of 3D supramolecular networks of molecules linked through hydrogen-bonding interactions. These polynitroxide radicals can serve as promising bridging or chelating ligands in the synthesis of transition-metal-based molecular magnets.
ABSTRACT
Two heteronuclear compounds (1 and 2) containing three ferric centers linked in facial-like mode with the magnetically silent hexacyanidocobaltate(III) anion were prepared and studied. The structural investigation revealed that both compounds are tetranuclear complexes with molecular formulas of [{Fe(L1)NC}3Co(CN)3]·2CH3OH·2.5CH3CN (1) and [{Fe(L2)NC}3Co(CN)3]·2H2O·1CH3OH (2). The magnetic properties of both complexes are controlled by the molecular design of the corresponding pentadentate Schiff base anions L12- and L22-. While compound 2 with a symmetric ligand prepared from salicylaldehyde shows high-spin state properties, compound 1 containing the asymmetric ligand with naphthalene units either is low-spin in its solvated form or shows a gradual but hysteretic spin crossover event when desolvated. The magnetic behavior was analyzed with respect to the Ising-like model and spin Hamiltonian, respectively, and the results were confronted with ab initio calculations. Additionally, the influence of structural features, lattice solvent molecules, the distribution of electronic terms, and active orbitals on the spin state properties of reported complexes is discussed.
ABSTRACT
A tridentate ligand L (2,6-bis(1-(3,5-di-tert-butylbenzyl)-1H-benzimidazol-2-yl)pyridine) was synthesized and used for the preparation of three pentacoordinated Co(ii) complexes of formula [Co(L)X2] (where X = NCS- for 1, X = Cl- for 2 and X = Br- for 3) and one ionic compound 4 ([Co(L)2]Br2·2CH3OH·H2O) containing a hexacoordinated Co(ii) centre. Static magnetic data were analysed with respect to the spin (1-3) or the Griffith-Figgis (4) Hamiltonian. Ab initio calculations enable us to identify the positive axial magnetic anisotropy parameter D accompanied by a significant degree of rhombicity in the reported complexes. Also, magneto-structural correlation was outlined for this class of compounds. Moreover, all four compounds exhibit slow relaxation of magnetisation at an applied static magnetic field with either both low- and high-frequency relaxation channels (3) or a single high-frequency relaxation process (1, 2 and 4). The interplay between the stereochemistry of coordination polyhedra, magnetic anisotropy and the relaxation processes was investigated and discussed in detail.
ABSTRACT
Various substituted 2-hydroxybenzophenones were combined with aliphatic linear triamines to form pentadentate Schiff base ligands. Twelve new iron(III) complexes with the general formula [Fe(Ln )X].mCH3 CN (n=1-10; X=N3- , NCS- or NCSe- ; m=0-2) have been synthesized, and spectrally as well as structurally characterized. The structural analysis revealed a notable dependence of coordination polyhedra deformation as well as the spatial configuration of donor atoms on the length and symmetry of the Schiff base ligands. The magnetic properties of the compounds were investigated and the permanent high-spin state (S=5/2) for all reported compounds was established, and allowed calculation of zero-field-splitting parameters as well as coupling constants, which were further confirmed with DFT calculations. The solid-state EPR spectra were recorded at 293â K and 98â K, and in accordance with the magnetic measurements, showed a high-spin state in the measured temperature range.
ABSTRACT
A series of novel iron(III) complexes of the general formula [Fe(L)X] (where L is a dianion of pentadentate Schiff base ligand N,N'-bis({2-hydroxy-3,5-dimethylphenyl}phenyl)methylidene-1,6-diamino-3-azapentane=H2 L1 for 1 and 2; N,N'-bis({2-hydroxy-3-ethoxyphenyl}methylidene)-1,6-diamino-3-azapentane=H2 L2 for 3 and 3â C3 H6 O) and X is terminal pseudohalido ligand (X=N3 for 1, X=NCS for 2, and X=NCSe for 3 and 3â C3 H6 O) were synthesized and thoroughly characterized. Magnetic measurements revealed the above room temperature spin crossover for isomorphic complexes 1 and 2 (T1/2 =441â K and T1/2 =435â K, respectively), whereas the solvent-free complex 3 showed a half complete spin crossover (T1/2 =250â K), which was detected by variable temperature crystallography as well. On the other hand, solvated complex 3â C3 H6 O exhibited permanent high spin state behaviour and either recrystallization or in situ thermal desolvation converts 3â C3 H6 O to solvent-free and spin-crossover-active form 3. Magnetic properties of all the reported complexes were also supported by EPR spectroscopy experiments and in addition, DFT and ab initio calculations were employed for the evaluation of the g-factor and zero field splitting parameters.
ABSTRACT
Entecavir (ETV) is one of the most potent agents for the treatment of the hepatitis B viral infection. The drug is principally eliminated by the kidney. The goal of this study was to investigate the potential of ETV to interact in vitro with the renal SLC transporters hOAT1, hOCT2, hCNT2 and hCNT3. Potential drug-drug interactions of ETV at the renal transporters with antiviral drugs known to be excreted by the kidney (adefovir, tenofovir, cidofovir) as well as transporter-dependent cytotoxicity were also examined. Interactions with the selected transporters along with cytotoxicity were studied in several transiently transfected cellular models using specific substrates and inhibitors. ETV was found to be both a substrate and inhibitor of hOAT1 (IC50 = 175.3 µM), hCNT2 (IC50 = 241.9 µM) and hCNT3 (IC50 = 278.4 µM) transporters, although it interacted with the transporters with relatively low affinities. ETV inhibited the cellular uptake of adefovir, tenofovir, and cidofovir by hOAT1; however, effective inhibition was shown at ETV concentrations exceeding therapeutic levels. In comparison with adefovir, tenofovir, and cidofovir, ETV displayed no transporter-mediated cytotoxicity in cells transfected with hOAT1, hCNT2, and hCNT3. No significant interaction of ETV with hOCT2 was detected. The study demonstrates interactions of ETV with several human renal transporters. For the first time, an interaction of ETV with the hCNTs was proved. We show that the potency of ETV to cause nephrotoxicity and/or clinically significant drug-drug interactions related to the tested transporters is considerably lower than that of adefovir, tenofovir, and cidofovir.
ABSTRACT
The mononuclear compound (1) [Fe(II)(L)(2)](BF(4))(2) (L = 4-ethynyl-2,6-bis(pyrazol-1-yl)pyridine) was prepared and structurally as well as magnetically characterised. The crystallisation revealed the formation of two polymorphs--the orthorhombic 1A and the tetragonal form 1B. A third, intermediate phase 1C was found exhibiting a different orthorhombic space group. Reversibility of the phase transition between 1A and 1C was studied by variable-temperature single-crystal and powder X-ray diffraction studies, while an irreversible phase transition was observed for the transition of 1Bâ1C. The magnetic studies show that the 1Aâ1C transition is accompanied by a very abrupt spin transition (ST) with 8 K hysteresis width (T(1/2)(↓) = 337 K, T(1/2)(↑) = 345 K). The ST was confirmed by Mössbauer spectroscopy as well as by DSC studies. In contrast, the 1B polymorph remained low-spin up to 420 K. In conclusion, a full cycle of intertwined phase- and spin-conversions of three polymorphs could be proven following the general scheme 1Bâ1Câ1A.
ABSTRACT
A series of 3-aryl-5-acyloxymethyl-5,6-dihydro-2H-pyran-2-ones, related to highly antifungally active butenolides, was synthesized via cyclization of substituted δ-hydroxy acids as the key step, and evaluated for their in vitro antifungal activity and cytostatic activity. While the extension of the furanone ring to pyranone led to a complete loss of the antifungal effect, some of the compounds displayed promising effect against several cell lines, including the resistant colorectal carcinoma cells.
Subject(s)
Antifungal Agents/chemistry , Cytostatic Agents/chemistry , Furans/chemistry , Pyrans/chemistry , Animals , Antifungal Agents/chemical synthesis , Antifungal Agents/pharmacology , Cell Line, Tumor , Cytostatic Agents/chemical synthesis , Cytostatic Agents/pharmacology , Furans/chemical synthesis , Furans/pharmacology , Humans , MiceABSTRACT
Biologically interesting 2-substituted 4-alkylidene pentenolides were prepared with complete control of regio- and stereoselectivity from 2-iodo allylic alcohols via an array of Pd-catalyzed processes, including alkynylation with methyl propiolate, tributyltin hydride addition, and alpha-functionalization. Some of the compounds possess selective cytostatic activity against ovarian carcinoma HeLa S3 and leukemia CCRF-CEM cell lines.
Subject(s)
Alkenes/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Propionates/chemical synthesis , Propionates/pharmacology , Animals , Antineoplastic Agents/chemistry , Benzene Derivatives/chemistry , Catalysis , Cell Line, Tumor , Humans , Inhibitory Concentration 50 , Mice , Palladium/chemistry , Propionates/chemistryABSTRACT
3-(4-bromophenyl)-5-acetyloxymethyl-2,5-dihydrofuran-2-one (LNO-18-22) is a representative member of a novel group of potential antifungal drugs, derived from a natural 3,5-disubstituted butenolide, (-)incrustoporine, as a lead structure. This lipophilic compound is characterized by high in vitro antifungal activity and low acute toxicity. For the purpose of in vivo studies, a new bioanalytical high-performance liquid chromatographic method with UV photodiode-array and mass spectrometric detection (HPLC-PDA-MS), involving a direct injection of diluted mouse urine was developed and used in the evaluation of the metabolic profiling of this drug candidate. The separation of LNO-18-22 and its phase I metabolites was performed in 37 min on a 125 mmx4 mm chromatographic column with Purospher RP-18e using an acetonitrile-water gradient elution. Scan mode of UV detection (195-380 nm) was employed for the identification of the parent compound and its biotransformation products in the biomatrix. Finally, the identity of LNO-18-22 and its metabolites was confirmed using HPLC-MS analyses of the eluate. These experiments demonstrated the power of a comprehensive analytical approach based on the combination of xenobiochemical methods and the results from tandem HPLC-PDA-MS (chromatographic behaviour, UV and MS spectra of native metabolites versus synthetic standards). The chemical structures of five phase I LNO-18-22 metabolites and one phase II metabolite were elucidated in the mouse urine, with two of these metabolites having very unexpected structures.